Annotation Detail
Information
- Associated Genes
- ALK
- Associated Variants
- ALK ALK FUSIONS ALK ALK FUSIONS
- Associated Disease
- cancer
- Source Database
- CIViC Evidence
- Description
- Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/2952
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1
- Variant URL
- https://civic.genome.wustl.edu/links/variants/499
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Cancer
- Evidence Direction
- Supports
- Drug
- Entrectinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 28183697
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Entrectinib | Sensitivity | true |